-
Forex Expo Dubai to Take Place as Scheduled on 22–23 September 2026
-
Ethiopia boosts drone production to fight rebels
-
Russia pounds Kyiv, ending three-day halt for US talks
-
Yemen rebels hit Saudi Arabia with wave of strikes, wounding 73
-
Flights resume gradually in Indonesia after volcanic eruption
-
Nepalis mark a year since deadly protests that toppled government
-
French AI firm Mistral valued at 21 bn euros after latest funding
-
Rubio launches Latin America tour to cement US influence
-
Sweden heads to the polls in close election race
-
France tries 14 over deadliest Channel migrant crossing disaster
-
Australia's Big Bash T20 teams face sale to private investors
-
Australia threatens hefty fines if big tech fails 'duty of care'
-
Russia resumes strikes on Kyiv after three-day halt
-
Zverev romps into quarter-finals as Darderi downed
-
Canada's counter-tariffs take effect on various US goods
-
Kauai on tornado watch as Hurricane Lowell nears Hawaiian islands
-
China's trade booms as focus turns to expected Trump-Xi summit
-
Pakistan roll the dice in search of consolation win over England
-
Is Champions League three-peat really possible for PSG?
-
Yen extends gains as traders eye rate hike, tech rallies again
-
Russia pummels Kyiv after three-day halt
-
'The ber months': Christmas arrives early in the Philippines
-
Mongolians wait hours for fuel as reliance on Russia bites
-
N. Korea calls Russia bridge a sign of tighter ties
-
Blockx first Belgian man to reach US Open quarter-finals
-
US sanctions threaten to crush Iranian students' dreams
-
Praying for rain as fires, haze plague Indonesian Borneo
-
Former champ Gauff holds off Jovic to reach US Open quarter-finals
-
Rybakina tops Osaka, sets US Open quarter-final clash with Zheng
-
Equitech-Bio Expands Reagent Portfolio with New IgG Offering and Publication-Backed Product Validation from Bioz
-
Apex Expands Trinity Zone with Step-out Hole Returning 197.5 m Interval of 2.12% REO at the Rift Rare Earth Project in SE Nebraska
-
Battery X Metals to Appoint Accomplished Technology and Consumer Brands Executive Nicholas Reichenbach to Board of Directors
-
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
-
Guardian Metal Resources PLC Announces Admission to FTSE AIM 50 Index
-
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 08
-
Gaming Realms PLC Announces Interim Results
-
Osaka seeks answers to nagging achilles injury after US Open exit
-
Panama Canal considering more cuts in transits due to El Nino
-
Flight data recorders recovered from Amazon cargo plane crash
-
Maresca agrees with Haaland that players started season jaded
-
Super Bowl rematch kicks off NFL season as league expands global reach
-
Hurricane warning issued for westernmost Hawaiian islands
-
Alcaraz faces Shelton in blockbuster US Open quarter-final
-
UK PM denounces 'politics of poison' after anti-migrant protests
-
Trump threatens sales in US of Canadian aircraft maker Bombardier
-
Comeback queen Zheng strikes again for US Open quarter-final berth
-
Eiffel Tower closed in row over women removed for Hindu group
-
Third absence for injured Hadjar as Lawson fills in again in Spain
-
Willemse replaces Kolbe for Springboks' All Blacks series decider
Equitech-Bio Expands Reagent Portfolio with New IgG Offering and Publication-Backed Product Validation from Bioz
PALO ALTO, CA / ACCESS Newswire / September 8, 2026 / Bioz, Inc., the scientific marketing platform that transforms peer-reviewed research into evidence-rich product experiences, today announced the continued expansion of its collaboration with Equitech-Bio, a trusted supplier of serum proteins, immunoglobulins, antisera, and other biological reagents for research, diagnostic development, and bioprocessing applications.
As Equitech-Bio prepares to introduce a new reagent-grade IgG product, the company is leveraging Bioz to place greater visibility on the scientific evidence supporting its most important product lines. Through Bioz Badges embedded on individual product webpages and a centralized Bioz Content Hub, researchers can access relevant peer-reviewed evidence while evaluating Equitech-Bio reagents.
The new reagent-grade IgG offering will expand Equitech-Bio's broad selection of immunoglobulins from multiple animal species. Together with the company's established animal IgG portfolio, the new product will give laboratories another high-quality option for research and development workflows in which consistency, purity, and reliable performance are essential.
"Researchers need more than a product specification, they need confidence that a reagent can perform in the applications that matter to them," said Dakota Howell, Vice President of Sales and Marketing at Equitech-Bio. "As we introduce our new reagent-grade IgG and continue to spotlight our antisera, BSA, and animal IgG portfolios, Bioz helps us place peer-reviewed evidence directly beside the products. This gives customers a clearer, faster way to evaluate their options and move forward with confidence."
Equitech-Bio's portfolio supports a wide range of experimental and manufacturing needs. Its antisera offerings include custom and species-specific solutions, while its BSA portfolio includes multiple grades and purification formats for applications such as assay development, cell culture, diagnostics, and protein stabilization. The company's animal IgG selection spans numerous species and formats, enabling researchers to identify products suited to their specific protocols.
On participating product webpages, Bioz Badges transform published product citations into an interactive research experience. Scientists can review relevant article excerpts, explore how a reagent has been used in published experiments, and view Bioz Stars ratings without interrupting the product-evaluation process. The Bioz Content Hub brings Equitech-Bio's broader publication record together in one searchable location, helping researchers begin with the scientific literature and navigate efficiently to the products most relevant to their work.
The Bioz platform updates continuously as new peer-reviewed research becomes available. This gives Equitech-Bio a dynamic way to support both established products and new launches with current scientific evidence, while helping its sales and marketing teams understand which products, applications, and publications are generating the greatest interest.
"Equitech-Bio's decision to connect its new reagent-grade IgG and core reagent portfolios with publication-backed evidence reflects a strong commitment to transparent product evaluation," said Dr. Karin Lachmi, Co-Founder and Chief Revenue Officer at Bioz. "Whether scientists are selecting antisera, BSA, or an animal IgG product, Bioz gives them immediate access to evidence that can help them make informed decisions with greater confidence."
About Bioz
Bioz is the world's most advanced citation-based data platform for scientific research, offering evidence-backed product ratings and recommendations to guide scientists toward the most validated products and services for their discoveries. Bioz's solutions for suppliers include Bioz Badges and Bioz Content Hubs, web-based widgets that enhance user engagement and increase sales conversion.
About Equitech Bio
Equitech Bio supplies high-quality biological reagents to laboratories, diagnostic manufacturers, academic institutions, and biotechnology and pharmaceutical organizations worldwide. With more than 30 years of commitment to the research industry, the company offers a broad portfolio of albumins, bovine serum albumin, immunoglobulins, antisera, animal serum and plasma, complement serum, and human biological products. Equitech-Bio also provides custom antisera and specialized processing options to support application-specific requirements, with a focus on product consistency, dependable performance, responsive service, and flexible ordering.
Helpful Links
For more information about Bioz solutions for suppliers, please reach out to [email protected].
SOURCE: Bioz, Inc.
View the original press release on ACCESS Newswire
A.Moore--AT